Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats non–central nervous system manifestations of acid sphingomyelinase deficiency…. Sold as Xenpozyme. Every FDA application for this active ingredient. Boxed warningIn shortageOrphan exclusivity to Aug 31, 2029
As of Nov 22, 2026, FDA lists 1 application for Olipudase alfa-rpcp (sold as Xenpozyme), first approved Aug 31, 2022, with 0 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Xenpozyme
Part D
$0
−100%
0
Xenpozyme
Part B
$0
−100%
0
Medicaid spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Xenpozyme
$23.6M for 362 prescriptions, +60% on 2024
How its trials ended
5 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Met its primary endpoint240%Met its primary endpointCount2Share40%
Ongoing240%OngoingCount2Share40%
Completed, result not reported120%Completed, result not reportedCount1Share20%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
First approved in Japan 5 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Xenpozyme, new ingredientA drug with a new active ingredient indicated for the treatment of acid sphingomyelinase deficiency. · Sanofi K.K. · Mar 28, 2022 · Review report
Approvals in Canada (Health Canada)
First approved in Canada 18 months after the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA